Metabolic syndrome in patients with prostate cancer undergoing androgen suppression

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683 Makshida, 2006, Hypogonadism and metabolic syndrome: implications for testosterone replacement, J Urol, 174, 827, 10.1097/01.ju.0000169490.78443.59 Morote, 2013, Metabolic syndrome increases the risk of aggressive prostate cancer detection, BJU Int, 111, 1031, 10.1111/j.1464-410X.2012.11406.x Terrier, 2013, Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone, Prog Urol, 23, 88, 10.1016/j.purol.2012.09.008 Barry, 2006, The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study, BJU Int, 98, 973, 10.1111/j.1464-410X.2006.06416.x Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Laaksonen, 2004, Testostetone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men, Diabetes Care, 27, 1036, 10.2337/diacare.27.5.1036 Lu-Yao, 2004, Changing patterns in competing causes of death in men with prostate cancer: a population based study, J Urol, 171, 2285, 10.1097/01.ju.0000127740.96006.1a Smith, 2002, Changes in body composition during androgen deprivation therapy for prostate cancer, J Clin Endocrinol Metab, 87, 599, 10.1210/jcem.87.2.8299 Braga-Basaria, 2006, Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy, J Clin Oncol, 24, 3979, 10.1200/JCO.2006.05.9741 Basaria, 2002, Long-term effects of androgen deprivation therapy in prostate cancer patients, Clin Endocrinol, 56, 779, 10.1046/j.1365-2265.2002.01551.x Smith, 2001, The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer, J Clin Endocrinol Metab, 86, 4261, 10.1210/jcem.86.9.7851 Dockery, 2003, Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia, Clin Sci, 104, 195, 10.1042/CS20020209 Basaria, 2006, Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy, Cancer, 106, 581, 10.1002/cncr.21642 Cleffi, 2011, Terapia de privación de andrógenos y obesidad mórbida: ¿tienen en común el riesgo cardiovascular por síndrome metabólico?, Actas Urol Esp, 35, 259, 10.1016/j.acuro.2011.01.011 International Diabetes Federation (IDF), 2005 Smith, 2008, Metabolic changes during gonadotrophin-releasing hormone agonist therapy for prostate cancer: differences from classic metabolic syndrome, Cancer, 112, 2188, 10.1002/cncr.23440 Kahn, 2005, The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes, Diabetes Care, 28, 2289, 10.2337/diacare.28.9.2289 Saylor, 2013, Metabolic complications of androgen deprivation therapy for prostate cancer, J Urol, 189, S34, 10.1016/j.juro.2012.11.017